Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods
— AR201 for Egg Allergy Phase 2 Initiation Planned for 2019 — — Michael Foods Is the Largest U.S. Processor of Value-Added Eggs — BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 20, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially
Toggle Summary Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children
BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 19, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has initiated POSEIDON ( P eanut O ral Immunotherapy S tudy of E arly I
Toggle Summary Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th
BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 6, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 12, 2018 .
Toggle Summary Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 28, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science.
Toggle Summary Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine
— Treatment with AR101 significantly increased the amount of peanut protein tolerated and reduced the number and severity of reactions to peanut protein — — Aimmune conference call Monday, November 19 at 8:00 a.m. Eastern — BRISBANE, Calif. --(BUSINESS WIRE)--Nov.
Toggle Summary Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science
— Nestlé Health Science to Invest $98 Million in Aimmune through the Purchase of 3.24 Million Shares of Aimmune Stock at $30.27 per Share — — Companies Extend Existing Strategic Collaboration Agreement Focused on Offering Innovative Food Allergy Therapies — — Nestlé Health Science CEO Greg Behar
Toggle Summary Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights
Recently completed Phase 3 RAMSES study confirms safety profile of AR101 in peanut-allergic children and teens BLA submission for AR101 on track for December 2018 Management to host analyst event on Wednesday, December 12 th , in New York BRISBANE, Calif. --(BUSINESS WIRE)--Nov.
Toggle Summary Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting
— Oral Presentation on Data from Aimmune’s Pivotal Phase 3 PALISADE Trial — — Additional Oral and E-Poster Presentations on AR101, Peanut Allergy and Oral Immunotherapy — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 8, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
Toggle Summary Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 2, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann , M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors,
Toggle Summary Aimmune Therapeutics to Participate in Upcoming Investor Conferences
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 1, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of senior management will participate in the following investor conferences: Stifel 2018